When upper respiratory infection cases were categorized by severity, no meaningful differences were identified between the SYK and/or BTK inhibitors and placebo groups for either grade 1–2 (RR 1.39; 95%CI: 0.59 – 3.26, p=0.45, I2 = 53%, random-effect model) or grade ≥3 events (RR 0.90; 95%CI: 0.15 – 5.47, p=0.91, I2 = 0%, random-effect model) (Table 3). The gene discussed is BTK; the disease is respiratory tract infectious disorder.